08/06/2024 | Press release | Distributed by Public on 08/06/2024 14:47
| | |
Per Share
|
| |
Total
|
|
Public offering price
|
| | | | | | |
Underwriting discounts and commissions(1)
|
| | | | | | |
Proceeds, before expenses, to us
|
| | | | | | |
| | |
Page
|
| |||
Prospectus supplement | | | | | | | |
About This Prospectus Supplement
|
| | | | S-ii | | |
Summary
|
| | | | S-1 | | |
Risk Factors
|
| | | | S-6 | | |
Special Note Regarding Forward-Looking Statements
|
| | | | S-9 | | |
Use of Proceeds
|
| | | | S-11 | | |
Dilution
|
| | | | S-12 | | |
Material U.S. Federal Income and Estate Tax Consequences for Non-U.S. Holders of Our Common
Stock |
| | | | S-14 | | |
Underwriting
|
| | | | S-17 | | |
Legal Matters
|
| | | | S-28 | | |
Experts
|
| | | | S-28 | | |
Where You Can Find More Information
|
| | | | S-28 | | |
Incorporation by Reference
|
| | | | S-29 | | |
|
About This Prospectus
|
| | | | 1 | | |
|
Where You Can Find More Information
|
| | | | 2 | | |
|
Incorporation by Reference
|
| | | | 3 | | |
|
The Company
|
| | | | 4 | | |
|
Risk Factors
|
| | | | 5 | | |
|
Special Note Regarding Forward-Looking Statements
|
| | | | 6 | | |
|
Use of Proceeds
|
| | | | 7 | | |
|
Description of Capital Stock
|
| | | | 8 | | |
|
Description of Debt Securities
|
| | | | 12 | | |
|
Description of Warrants
|
| | | | 20 | | |
|
Description of Rights
|
| | | | 22 | | |
|
Description of Stock Purchase Contracts
|
| | | | 23 | | |
|
Description of Units
|
| | | | 24 | | |
|
Plan of Distribution
|
| | | | 25 | | |
|
Legal Matters
|
| | | | 26 | | |
|
Experts
|
| | | | 26 | | |
| | |
Phase 1
(N=12) |
| |
Phase 2
(N=23) |
| |
Phase 1/2 Total
(N=35) |
|
Complete Response | | | | | | | | | | |
No surgeries needed during 12 months post-treatment
|
| |
50% (6/12)
|
| |
52% (12/23)
|
| |
51% (18/35)
|
|
Decrease in Rate of Surgery | | | | | | | | | | |
12 months post-treatment compared to 12 months pre-treatment
|
| |
83% (10/12)
|
| |
87% (20/23)
|
| |
86% (30/35)
|
|
| | |
1 x 1011 PU
(N = 3) |
| |
5 x 1011 PU
(N=35) |
| ||||||
| | |
Grade 1
|
| |
Grade 2
|
| |
Grade 1
|
| |
Grade 2
|
|
Event | | |
(N, %)
|
| |
(N, %)
|
| |
(N, %)
|
| |
(N, %)
|
|
Chills
|
| |
-
|
| |
-
|
| |
25 (71%)
|
| |
-
|
|
Fatigue
|
| |
-
|
| |
-
|
| |
28 (80%)
|
| |
2 (6%)
|
|
Fever
|
| |
-
|
| |
-
|
| |
24 (69%)
|
| |
-
|
|
Headache
|
| | | | | | | |
2 (6%)
|
| | | |
Hyperhidrosis
|
| |
-
|
| |
-
|
| |
2 (6%)
|
| |
-
|
|
Injection site reaction
|
| |
3 (100%)
|
| |
-
|
| |
34 (97%)
|
| |
-
|
|
Myalgia
|
| |
-
|
| |
-
|
| |
9 (26%)
|
| |
2 (6%)
|
|
Nausea
|
| |
-
|
| |
-
|
| |
8 (23%)
|
| |
-
|
|
Vomiting
|
| |
-
|
| |
-
|
| |
2 (6%)
|
| |
-
|
|
|
Public offering price per share
|
| | | | | | | | | $ | | | |
|
Net tangible book value (deficit) per share as of March 31, 2024
|
| | | $ | 0.13 | | | | | | | | |
|
Increase in net tangible book value per share attributable to purchasers in this offering
|
| | | $ | | | | | | | | | |
|
As adjusted net tangible book value per share immediately after this offering
|
| | | | | | | | | $ | | | |
|
Dilution per share to purchasers in this offering
|
| | | | | | | | | $ | | | |
Name
|
| |
Number of
Shares |
| |||
Stifel, Nicolaus & Company, Incorporated
|
| | | | | | |
Total
|
| | | | | | |
| | | | | | | | |
Total
|
| |||||||||
| | |
Per Share
|
| |
No Exercise
|
| |
Full Exercise
|
| |||||||||
Offering price
|
| | | $ | | | | | $ | | | | | $ | | | |||
Underwriting discounts and commissions
|
| | | $ | | | | | $ | | | | | $ | | | |||
Proceeds to us, before expenses
|
| | | $ | | | | | $ | | | | | $ | | | |
| | |
Page
|
| |||
About This Prospectus
|
| | | | 1 | | |
Where You Can Find More Information
|
| | | | 2 | | |
Incorporation by Reference
|
| | | | 3 | | |
The Company
|
| | | | 4 | | |
Risk Factors
|
| | | | 5 | | |
Special Note Regarding Forward-Looking Statements
|
| | | | 6 | | |
Use of Proceeds
|
| | | | 7 | | |
Description of Capital Stock
|
| | | | 8 | | |
Description of Debt Securities
|
| | | | 12 | | |
Description of Warrants
|
| | | | 20 | | |
Description of Rights
|
| | | | 22 | | |
Description of Stock Purchase Contracts
|
| | | | 23 | | |
Description of Units
|
| | | | 24 | | |
Plan of Distribution
|
| | | | 25 | | |
Legal Matters
|
| | | | 26 | | |
Experts
|
| | | | 26 | | |
|
Stifel
|
|